DOI QR코드

DOI QR Code

Chemotherapy and Late Course Three Dimensional Conformal Radiotherapy for Treatment of Patients with Stage III Non-small Cell Lung Cancer

  • Liu, Yang-Chen (Department of Radiation Oncology, The People Hospital of Taixing City) ;
  • Zhou, Shao-Bing (Department of Radiation Oncology, The People Hospital of Taixing City) ;
  • Gao, Fei (Department of Radiation Oncology, The People Hospital of Taixing City) ;
  • Ye, Hong-Xun (Department of Radiation Oncology, The People Hospital of Taixing City) ;
  • Zhao, Ying (Department of Radiation Oncology, The People Hospital of Taixing City) ;
  • Yi, Xiao-Xiang (Department of Radiation Oncology, The People Hospital of Taixing City) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Xiang, Jin (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2013.04.30

Abstract

Objective: To compare the efficacy and complications of chemotherapy and late course three-dimensional conformal radiotherapy (3DCRT) in treating patients with stage III non-small cell lung cancer (NSCLC). Patients and Methods: All patients were divided into two groups: to receive chemotherapy and late course 3DCRT (3DCRT group), or chemotherapy and conventional fraction radiation (control group). In the 3DCRT-group, patients were given 6~15 MV X-rays with a total dose of 40 Gy, followed by 3DCRT, 2.5 Gy~3.0 Gy per fraction, 1 fraction/every day, total 68 Gy~70 Gy; in the control group, with conventional fraction radiation the total dose was 64~66 Gy. The chemotherapy regimen in both cases was EP (VP-16 and DDP). Results: Sixty four patients with stage III NSCLC were divided into two groups: 32 patients into 3DCRT, 32 into the control group. One and 2-year survival rates in 3DCRT and control group were 87.5%, 56.3%mad 65.6%, 34.4%, respectively (P<0.05); local control rates were 90.6%, 81.3% and 65.6%, 53.1%, respectively (P<0.05). Conclusion: Chemotherapy and late course 3DCRT is associated with improved survival rate in patients with stage III NSCLC with good tolerability.

References

  1. Emami B, Kaiser L, Simpson J, et al (1997). Postoperative radiation therapy in non-small cell lung cancer. Am J Clin Oncol, 20, 441-8. https://doi.org/10.1097/00000421-199710000-00003
  2. Ferlay J, Bray F, Pisani P, et al (2001). GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No 5. Lyon: IARC Press.
  3. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  4. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  5. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  6. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
  7. Li CG, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  8. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  9. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  10. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  11. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  12. Luo J, Wu FY, Li AW, et al (2012). Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study. Asian Pac J Cancer Prev, 13, 4703-6. https://doi.org/10.7314/APJCP.2012.13.9.4703
  13. Non-Small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer. A metaanalysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899-909. https://doi.org/10.1136/bmj.311.7010.899
  14. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  15. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  16. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  17. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  18. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.

Cited by

  1. Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.5699
  2. Clinical Observation and Prognostic Analysis of Pemetrexed plus Platinum as First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6267
  3. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  4. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  5. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  6. Experimental Study of Endostar Injection Concomitant with Cryoablation on Lung Adenocarcinoma A549 Xenografts vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6697
  7. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  8. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  9. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  10. Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3851
  11. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  12. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  13. Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4205
  14. Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4369
  15. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  16. Variation of Blood T Lymphocyte Subgroups in Patients with Non- small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4671
  17. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  18. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  19. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  20. Further Study on Pemetrexed based chemotherapy in Treating Patients with Advanced Gastric Cancer (AGC) vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6587
  21. Evaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7371
  22. Clinical Outcome of Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: The Kyung Hee University Medical Center Experience vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1545
  23. Phase II Study on Dose Escalating Schedule of Paclitaxel Concurrent with Radiotherapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1699
  24. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  25. Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3451
  26. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  27. Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10241
  28. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4891
  29. Analysis on Early Detection of Lung Cancer by PET/CT Scan vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2215
  30. Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2987
  31. Radioactive Seed Implantation and Lobaplatin Chemotherapy Are Safe and Effective in Treating Patients with Advanced Lung Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4003
  32. Early Growth Response Protein-1 Involves in Transforming Growth factor-β1 Induced Epithelial-Mesenchymal Transition and Inhibits Migration of Non-Small-Cell Lung Cancer Cells vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4137
  33. Clinical Evaluation and Therapeutic Monitoring Value of Serum Tumor Markers in Lung Cancer vol.31, pp.1, 2016, https://doi.org/10.5301/jbm.5000177